Huan MoPartner
Ms. Mo Huan joined Jiayuan’s Shanghai office as a partner in 2020. Ms. Mo focuses her practice on advising life science and high technology companies with general commercial intellectual property (“IP”) issues and regulatory matters, including IP transactions, general IP advice, technology licensing & collaborations, FDA regulatory counseling,, digital health, cybersecurity & data privacy, IP enforcement and anti-piracy, IP litigation, unfair competition, and trade secret proctection. She has advised companies in a variety of industries, including pharmaceutical, medical device, biotechnology, health food, food and beverage, food additive, cosmetic, electronics and telecommunications, social media networking, software, jewelry, alcohol, and luxury fashion brands. Before joining Jiayuan, Ms. Mo worked at a leading US law firm.
Office：Shanghai
Tel：8621-60407105
E-mail：mohuan@jiayuan-law.com
Language：Chinese, English
Representative Deals
- IP
Assisted a leading Chinese bio-pharmaceuticals company in several in-licensing and out-licensing arrangements.
Advised a U.S. clothing corporation in the negotiation of a collaboration with a large Chinese clothing company to co-develop the China market.
Advised a global pharmaceutical company on IP and regulatory issues associated with its acquisition of assets from a Chinese pharmaceutical manufacturer.
Advised a US medical device company on issues associated with localization of product manufacturing in China and the establishment of its green-field operation in China.
Advised a leading medical device company in trademark infringement litigations with strategy to defend against claims brought by its own distributors.
Advised institutional investors in the conduct of IP due diligence on issues ranging from assessment of IP asserts, freedom to operate assessment, and risk management advice of their potential investment in China.
Advised a leading Chinese mobile health company on its data privacy compliance program.
Advised pharmaceutical companies on issues related to patent non-infringement statement and data exclusivity protection in the process of drug registration.
Advised multinational companies on issues related to how to develop inventor rewards and remuneration policy in China.
Advised on various IP issues for a world leading alcohol company in China, including arranging for investigations, conducting negotiations with infringers, sending Cease & Desist Letters, drafting the settlement agreements, lobbying of the administrative authorities and filing civil lawsuits. - Life science Regulatory:
Advised institutional investors in the conduct of regulatory due diligence on issues ranging from product registration, compliance with GLP/GCP/GMP/GSP, and pharmacovigilance of their potential investment targets in China.
Advised multiple pharmaceutical companies on issues associated with negotiation of contracts with clinical sites to conduct clinical studies in China.
Advised several pharmaceutical companies on the feasibility analyses of innovative patient assistance programs and patient benefit management projects in China.
Routinely advises pharmaceutical and medical device companies on matters pertaining to clinical trials, product registration, recall, distribution, importation, pricing, reimbursement and product safety issues in China.
Routinely advises healthcare companies on product promotional practices, advertising activities, transparency in interactions with healthcare professional, direct-to-patient communication and matters related to code of conduct in China.
Advised a leading US-based medical device company on its response to an investigation initiated by NMPA on the supply of Research-Use-Only reagents to hospitals.
Advised several China-based pharmaceutical company on issues associated with two-invoice system for the MAH holder.
Advised a UK cosmetic company on matters pertaining to product registration, animal testing requirement and product labeling compliance in China.
Education
- 2010, Master from the Law School of Fudan University
- 2007, B.Sc (Bio-pharmaceutics) from South China Agriculture University
Bar Admission
- 2008, PRC
- 2013, PRC Patent Agent
Academic paper
- Co-author, “China’s FDA Reform Will Encourage Life Science Innovation”, Law360 (November 15, 2017)
- Co-author, “New China FDA Guidance May Speed Up Device Approvals”, Law360 (June 17, 2015)
